Cargando…

2701. Mycobacterial Immune Reconstitution Inflammatory Syndrome Following Hematopoietic Cell Transplantation for GATA2 Deficiency

BACKGROUND: Immune reconstitution inflammatory syndrome (IRIS) was first described in patients with HIV and opportunistic infections starting antiretroviral therapy, but may be seen following hematopoietic cell transplantation (HCT) in patients with pre-existing infections. GATA2 deficiency is a gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Epling, Brian P, Cuellar-Rodriguez, Jennifer, Arnold, Danielle, Avila, Daniele, Bauer, Thomas, Cole, Kristen, Daub, Janine, Duncan, Lisa, Gea-Banacloche, Juan, Ma, Stella, Merkel, Roxanne, Palmer, Cindy, Zerbe, Christa, Holland, Steven M, Sereti, Irini, Hickstein, Dennis, Manion, Maura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677727/
http://dx.doi.org/10.1093/ofid/ofad500.2312
_version_ 1785150198291365888
author Epling, Brian P
Cuellar-Rodriguez, Jennifer
Arnold, Danielle
Avila, Daniele
Bauer, Thomas
Cole, Kristen
Daub, Janine
Duncan, Lisa
Gea-Banacloche, Juan
Ma, Stella
Merkel, Roxanne
Palmer, Cindy
Zerbe, Christa
Holland, Steven M
Sereti, Irini
Hickstein, Dennis
Manion, Maura
author_facet Epling, Brian P
Cuellar-Rodriguez, Jennifer
Arnold, Danielle
Avila, Daniele
Bauer, Thomas
Cole, Kristen
Daub, Janine
Duncan, Lisa
Gea-Banacloche, Juan
Ma, Stella
Merkel, Roxanne
Palmer, Cindy
Zerbe, Christa
Holland, Steven M
Sereti, Irini
Hickstein, Dennis
Manion, Maura
author_sort Epling, Brian P
collection PubMed
description BACKGROUND: Immune reconstitution inflammatory syndrome (IRIS) was first described in patients with HIV and opportunistic infections starting antiretroviral therapy, but may be seen following hematopoietic cell transplantation (HCT) in patients with pre-existing infections. GATA2 deficiency is a genetic disorder with a marked susceptibility to mycobacterial infections, and is treated definitively with HCT. The clinical factors and pathogenesis of IRIS in HCT require further investigation. METHODS: We conducted a retrospective review of 32 patients with GATA2 deficiency and mycobacterial infections who completed > 6 months of follow-up after HCT. Uniform criteria were used to define cases of IRIS (Image 1). IRIS cases were classified as either early (post-HCT day < 60), intermediate (days 61-120), or late (day > 120). [Figure: see text] Criteria were adapted to hematopoietic cell transplantation from the AIDS Clinical Trial Group IRIS criteria. RESULTS: Clinical characteristics are shown in Image 2. IRIS was identified in 12 (35%) patients (Images 2-3). These patients were more likely to have disseminated infection (P=0.03), an elevated pre-HCT ferritin (P=0.03), and a lower day 30 post-HCT CD4 count (P=0.04). Median time to IRIS was 100 days (Image 4). Pre-transplant duration of mycobacterial therapy correlated with time to IRIS (Pearson’s r=0.58, P=0.05). Conditioning regimens using total body irradiation with or without cyclophosphamide were associated with longer time to IRIS (hazard ratio=0.04, P=0.02). A rise in CD3 chimerism was seen during early cases of IRIS, but not intermediate to late (P=0.002). IRIS emerged during tapering of systemic immunosuppressive therapy in 33% of cases. IRIS was managed conservatively (50%), by intensification of anti-mycobacterial treatment (8%) or by intensification of immunosuppression (42%). [Figure: see text] [Figure: see text] [Figure: see text] CONCLUSION: Development of mycobacterial IRIS after HCT for GATA2 deficiency was associated with disseminated infection, a high pre-transplant ferritin, and low day 30 CD4 count. These findings suggest that antigen burden, a hyperinflammatory state leading into transplantation, and CD4 nadir after HCT have a role in its pathogenesis. Early cases of IRIS may emerge during lymphoid engraftment and CD4 recovery, whereas late cases may emerge with decreases in immunosuppressive therapy and more intensive conditioning regimens. Clinical outcomes were similar to non-IRIS patients. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-10677727
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106777272023-11-27 2701. Mycobacterial Immune Reconstitution Inflammatory Syndrome Following Hematopoietic Cell Transplantation for GATA2 Deficiency Epling, Brian P Cuellar-Rodriguez, Jennifer Arnold, Danielle Avila, Daniele Bauer, Thomas Cole, Kristen Daub, Janine Duncan, Lisa Gea-Banacloche, Juan Ma, Stella Merkel, Roxanne Palmer, Cindy Zerbe, Christa Holland, Steven M Sereti, Irini Hickstein, Dennis Manion, Maura Open Forum Infect Dis Abstract BACKGROUND: Immune reconstitution inflammatory syndrome (IRIS) was first described in patients with HIV and opportunistic infections starting antiretroviral therapy, but may be seen following hematopoietic cell transplantation (HCT) in patients with pre-existing infections. GATA2 deficiency is a genetic disorder with a marked susceptibility to mycobacterial infections, and is treated definitively with HCT. The clinical factors and pathogenesis of IRIS in HCT require further investigation. METHODS: We conducted a retrospective review of 32 patients with GATA2 deficiency and mycobacterial infections who completed > 6 months of follow-up after HCT. Uniform criteria were used to define cases of IRIS (Image 1). IRIS cases were classified as either early (post-HCT day < 60), intermediate (days 61-120), or late (day > 120). [Figure: see text] Criteria were adapted to hematopoietic cell transplantation from the AIDS Clinical Trial Group IRIS criteria. RESULTS: Clinical characteristics are shown in Image 2. IRIS was identified in 12 (35%) patients (Images 2-3). These patients were more likely to have disseminated infection (P=0.03), an elevated pre-HCT ferritin (P=0.03), and a lower day 30 post-HCT CD4 count (P=0.04). Median time to IRIS was 100 days (Image 4). Pre-transplant duration of mycobacterial therapy correlated with time to IRIS (Pearson’s r=0.58, P=0.05). Conditioning regimens using total body irradiation with or without cyclophosphamide were associated with longer time to IRIS (hazard ratio=0.04, P=0.02). A rise in CD3 chimerism was seen during early cases of IRIS, but not intermediate to late (P=0.002). IRIS emerged during tapering of systemic immunosuppressive therapy in 33% of cases. IRIS was managed conservatively (50%), by intensification of anti-mycobacterial treatment (8%) or by intensification of immunosuppression (42%). [Figure: see text] [Figure: see text] [Figure: see text] CONCLUSION: Development of mycobacterial IRIS after HCT for GATA2 deficiency was associated with disseminated infection, a high pre-transplant ferritin, and low day 30 CD4 count. These findings suggest that antigen burden, a hyperinflammatory state leading into transplantation, and CD4 nadir after HCT have a role in its pathogenesis. Early cases of IRIS may emerge during lymphoid engraftment and CD4 recovery, whereas late cases may emerge with decreases in immunosuppressive therapy and more intensive conditioning regimens. Clinical outcomes were similar to non-IRIS patients. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10677727/ http://dx.doi.org/10.1093/ofid/ofad500.2312 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Epling, Brian P
Cuellar-Rodriguez, Jennifer
Arnold, Danielle
Avila, Daniele
Bauer, Thomas
Cole, Kristen
Daub, Janine
Duncan, Lisa
Gea-Banacloche, Juan
Ma, Stella
Merkel, Roxanne
Palmer, Cindy
Zerbe, Christa
Holland, Steven M
Sereti, Irini
Hickstein, Dennis
Manion, Maura
2701. Mycobacterial Immune Reconstitution Inflammatory Syndrome Following Hematopoietic Cell Transplantation for GATA2 Deficiency
title 2701. Mycobacterial Immune Reconstitution Inflammatory Syndrome Following Hematopoietic Cell Transplantation for GATA2 Deficiency
title_full 2701. Mycobacterial Immune Reconstitution Inflammatory Syndrome Following Hematopoietic Cell Transplantation for GATA2 Deficiency
title_fullStr 2701. Mycobacterial Immune Reconstitution Inflammatory Syndrome Following Hematopoietic Cell Transplantation for GATA2 Deficiency
title_full_unstemmed 2701. Mycobacterial Immune Reconstitution Inflammatory Syndrome Following Hematopoietic Cell Transplantation for GATA2 Deficiency
title_short 2701. Mycobacterial Immune Reconstitution Inflammatory Syndrome Following Hematopoietic Cell Transplantation for GATA2 Deficiency
title_sort 2701. mycobacterial immune reconstitution inflammatory syndrome following hematopoietic cell transplantation for gata2 deficiency
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677727/
http://dx.doi.org/10.1093/ofid/ofad500.2312
work_keys_str_mv AT eplingbrianp 2701mycobacterialimmunereconstitutioninflammatorysyndromefollowinghematopoieticcelltransplantationforgata2deficiency
AT cuellarrodriguezjennifer 2701mycobacterialimmunereconstitutioninflammatorysyndromefollowinghematopoieticcelltransplantationforgata2deficiency
AT arnolddanielle 2701mycobacterialimmunereconstitutioninflammatorysyndromefollowinghematopoieticcelltransplantationforgata2deficiency
AT aviladaniele 2701mycobacterialimmunereconstitutioninflammatorysyndromefollowinghematopoieticcelltransplantationforgata2deficiency
AT bauerthomas 2701mycobacterialimmunereconstitutioninflammatorysyndromefollowinghematopoieticcelltransplantationforgata2deficiency
AT colekristen 2701mycobacterialimmunereconstitutioninflammatorysyndromefollowinghematopoieticcelltransplantationforgata2deficiency
AT daubjanine 2701mycobacterialimmunereconstitutioninflammatorysyndromefollowinghematopoieticcelltransplantationforgata2deficiency
AT duncanlisa 2701mycobacterialimmunereconstitutioninflammatorysyndromefollowinghematopoieticcelltransplantationforgata2deficiency
AT geabanaclochejuan 2701mycobacterialimmunereconstitutioninflammatorysyndromefollowinghematopoieticcelltransplantationforgata2deficiency
AT mastella 2701mycobacterialimmunereconstitutioninflammatorysyndromefollowinghematopoieticcelltransplantationforgata2deficiency
AT merkelroxanne 2701mycobacterialimmunereconstitutioninflammatorysyndromefollowinghematopoieticcelltransplantationforgata2deficiency
AT palmercindy 2701mycobacterialimmunereconstitutioninflammatorysyndromefollowinghematopoieticcelltransplantationforgata2deficiency
AT zerbechrista 2701mycobacterialimmunereconstitutioninflammatorysyndromefollowinghematopoieticcelltransplantationforgata2deficiency
AT hollandstevenm 2701mycobacterialimmunereconstitutioninflammatorysyndromefollowinghematopoieticcelltransplantationforgata2deficiency
AT seretiirini 2701mycobacterialimmunereconstitutioninflammatorysyndromefollowinghematopoieticcelltransplantationforgata2deficiency
AT hicksteindennis 2701mycobacterialimmunereconstitutioninflammatorysyndromefollowinghematopoieticcelltransplantationforgata2deficiency
AT manionmaura 2701mycobacterialimmunereconstitutioninflammatorysyndromefollowinghematopoieticcelltransplantationforgata2deficiency